Predicting cetuximab efficacy in patients with advanced colorectal cancer

Ibrahim H Sahin
Christopher R Garrett

Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Abstract: Cetuximab has demonstrated activity, both as monotherapy, and in combination with cytotoxic chemotherapy, albeit modest. Efforts over the last decade have focused on determining which patient populations are most likely to benefit from this chimeric monoclonal antibody therapy. As the antibody targets the epidermal growth factor receptor (EGFR), cell surface expression by immunohistochemistry was hypothesized to be a biomarker of clinical efficacy; subsequent clinical trials have shown that this was not the case. Tumor KRAS mutation (the most frequently observed site is at codon 12) has been shown to be a negative biomarker (ie, a marker of cetuximab resistance); since 2008, treatment of patients with cetuximab has been restricted to those whose tumors do not harbor a KRAS mutation. There is considerable heterogeneity of KRAS mutations, and studies are ongoing to determine whether cetuximab resistance extends to those patients whose tumors have a KRAS codon 13, 61, and 164, mutation. EGFR gene copy, or more precisely a lack of increase in EGFR gene copy number, has been demonstrated to be a negative biomarker of EGFR efficacy; currently, it is not in routine use as a clinical standard of care. Tumor BRAF status, NRAS status, and PIK3CA mutation status are being evaluated as additional potential negative biomarkers of treatment efficacy. High expression of the receptor ligands epiregulin and amphiregulin has been shown to be a positive biomarker for treatment efficacy and is continuing to be studied clinically. After almost 10 years following the widespread introduction of cetuximab into the clinic as a treatment for metastatic colorectal cancer, the story of identifying suitable biomarkers of efficacy is still evolving. The tremendous tumor heterogeneity at the molecular level and the cell complexity of signaling pathways suggest that there is still a significant amount of work to be done to optimally define those patients most likely to benefit from this form of therapy.

Keywords: biomarkers, epidermal growth factor receptor, EGFR, KRAS mutation

Introduction
In February 2004, cetuximab became the first monoclonal antibody targeting the epidermal growth factor receptor (EGFR) to be approved for the treatment of metastatic colorectal cancer (CRC) in the United States; it received initial accelerated approval based upon observed objective response rates in clinical trials. EGFR is a member of the receptor tyrosine kinase family and found in the membrane of the epithelial cells lining in the surface of many organs, including the gastrointestinal system. EGFR mediates transduction of growth signals and has oncogenic activity in certain cancers (such as lung cancer and CRC), and its overexpression is associated with poorly differentiated histology, more advanced clinical stage, and an adverse prognosis. Therefore, EGFR presented an attractive potential therapeutic target for the treatment of a broad range of malignancies.
Murine antibodies with high affinity to EGFR, both agonist and antagonist, were generated by Drs Gordon Sato and John Mendelsohn, in 1982. Initial human Phase I studies of the compound M225 were performed in patients with advanced squamous cell carcinoma of the lung but were associated with the development of human anti-mouse antibody responses, limiting its clinical utility. A chimeric version of M225 (C225, cetuximab) was developed for human use in order to avoid anti-mouse antibody production. Studies have demonstrated that these antibodies can bind to EGFR, with a higher affinity than the natural ligands, and therefore may interrupt EGFR-dependent cell signaling. Preclinical studies of M225 and C225 have demonstrated efficacy in human epithelial tumor xenograft models; additionally, cetuximab was shown to be synergistic with topoisomerase I inhibitors. These preclinical observations were borne out in Phase II clinical trials, where cetuximab was demonstrated to have monotherapy activity in patients with chemotherapy-refractory CRC; in patients with irinotecan-refractory disease, the addition of cetuximab to irinotecan was shown to overcome resistance.

Despite the efficacy which led to accelerated approval (and full approval October 2007) following clinical evidence to support a survival advantage with its monotherapy use, it was realized that the majority of CRC patients with advanced metastatic disease, treated with cetuximab as monotherapy, appear not to benefit from therapy. Better identification of biomarkers of cetuximab efficacy would allow for more effective clinical use; this manuscript seeks to review the last decade of research regarding biomarkers of cetuximab efficacy in patients with CRC.

Clinical biomarkers of cetuximab efficacy
As with the receptor tyrosine kinase EGFR inhibitors gefitinib and erlotinib, in patients with advanced lung cancer, the degree of skin toxicity was correlated with treatment efficacy in multiple CRC clinical trials. Clinical trials have tried to exploit this observation with dose escalation of cetuximab in those patients who do not develop grade 2 acneiform rash; in a randomized Phase II study where this “dose-escalation-to-rash” strategy was utilized, the dose escalation arm was associated with a higher response rate (30% versus 38%) but not a superior overall survival (OS). This pharmacodynamics clinical observation is an interesting phenomenon of limited clinical utility.

EGFR mutation and cell surface expression
Initial clinical trials with cetuximab limited enrollment to those patients whose tumors demonstrated expression of EGFR by immunohistochemistry. Subsequent subset analysis of these studies demonstrated that the degree of EGFR expression by immunohistochemistry did not correlate with OS or objective response rate. Unlike non-small-cell lung cancer, de novo tumor EGFR mutations are uncommon in CRC (being present in less than 1% of the cases) and when present, usually do not represent activating mutations and are not predictors of response to cetuximab.

EGFR gene copy number
In a small number of patients (31) treated with cetuximab or panitumumab (a fully humanized anti-EGFR monoclonal antibody that binds at a different, albeit partially overlapping, epitope than cetuximab), it was noted that of the nine patients who responded to anti-EGFR monoclonal antibody therapy, eight had an increased EGFR copy number, as measured by fluorescent in situ hybridization (FISH) compared with only one of 21 of the nonresponders. A larger retrospective study evaluating 85 patients who received cetuximab monotherapy (5), or in combination with irinotecan (77) or oxaliplatin (3), and utilizing a scoring system (a positive score representing three or greater signals per nucleus or gene amplification), demonstrated that there was a statistical trend toward improved OS in time to progression and OS in those patients whose tumors were EGFR FISH positive. Limitations to the utility of EGFR gene copy number include significant within-sample and within-patient heterogeneity, and the lack of accepted cutoff values for increase gene copy number. Table 1 summarizes the studies evaluating EGFR gene copy number as a biomarker of anti-EGFR efficacy.

Whereas EGFR amplification is easily identified by FISH, and is associated with improved outcome with anti-EGFR antibodies, it occurs in less than 5% of patients. Rather than increased gene copy number of EGFR, the non-increase may be a more accurate negative biomarker (ie, predictor of lack of efficacy of anti-EGFR therapy), in that the majority of CRC patients who respond to anti-EGFR monoclonal antibody therapy have an increased EGFR copy number, but a minority of patients with tumors with an increased EGFR copy number respond to therapy. Patients whose tumors have a high EGFR copy number may not respond to anti-EGFR therapy due to downstream activation of KRAS, BRAF, or PIK3CA.

Tumor EGFR gene copy number was noted to vary among
different centers in one study, demonstrating the need for standardization of testing.33

**Tumor KRAS status**

As mentioned above, constitutive activation of signaling pathways downstream of the EGFR may lead to resistance of anti-EGFR strategies.34,35 Tumor KRAS mutations are present in approximately 40% of CRC;36 in codon 12, the mutations most commonly seen are G12C, G12R, G12S, G12A, G12D, and G12V, and in codon 13, the most commonly identified mutations are G13C, G13R, G13S, G13A, G13D, and G13R. Consistent with the belief that downstream constitutive activation of EGFR signaling would confer resistance to anti-EGFR monoclonal antibody therapy, an initial study demonstrated that the presence of an activating tumor KRAS mutation was a negative biomarker of cetuximab efficacy.37 Multiple large tissue samples correlated with tumor response and outcome with anti-EGFR therapy have confirmed this observation (Table 2).31,37–44 Although never confirmed in a prospective randomized trial, all of these retrospective tissue studies suggest that tumors with a KRAS codon 12 mutation are resistant to anti-EGFR therapy, particularly in comparison with KRAS wild-type tumors. Consistent with this data, use of cetuximab and panitumumab, by the manufacturer’s label, is restricted to patients with wild-type tumors. The data are less clear when patients who have a KRAS codon

**Table 1** EGFR GCN by FISH as a biomarker of cetuximab sensitivity

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of patients</th>
<th>Treatment</th>
<th>Method</th>
<th>Endpoint Response rate/time to progression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moroni et al34</td>
<td>31</td>
<td>Cetuximab or panitumumab</td>
<td>EGFR GCN FISH</td>
<td>ORR</td>
</tr>
<tr>
<td>Cappuzzo et al37</td>
<td>85</td>
<td>Cetuximab</td>
<td>Increased EGFR (&gt;2.92 EGFR gene copies per cell) by FISH</td>
<td>ORR</td>
</tr>
<tr>
<td>Italiano et al38</td>
<td>47</td>
<td>Cetuximab plus chemotherapy</td>
<td>EGFR GCN FISH</td>
<td>ORR</td>
</tr>
<tr>
<td>Sartore-Bianchi et al39</td>
<td>87</td>
<td>Phase III panitumumab versus best supportive care</td>
<td>EGFR GCN &lt;2.5/nucleus &lt;40% cells displaying Chromosome 7 polysomy (associated with inferior outcome)</td>
<td>PFS/OS</td>
</tr>
<tr>
<td>Personeni et al40</td>
<td>87</td>
<td>Cetuximab ± irinotecan</td>
<td>Increased mean EGFR GCN FISH</td>
<td>PFS/OS</td>
</tr>
<tr>
<td>Khambata-Ford et al41</td>
<td>80</td>
<td>Cetuximab</td>
<td>EGFR GCN by PCR increased</td>
<td>DCR</td>
</tr>
<tr>
<td>Laurent-Puig et al42</td>
<td>173</td>
<td>Cetuximab</td>
<td>EGFR polysomy or amplification</td>
<td>PFS/OS</td>
</tr>
</tbody>
</table>

**Abbreviations:** DCR, disease control rate; EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization; GCN, gene copy number; ORR, overall response rate; OS, overall survival; PCR, polymerase chain reaction; PFS progression-free survival; TTP, time to progression.

---

**Table 2** Studies demonstrating tumor KRAS mutation as a negative predictor of anti-EGFR response

<table>
<thead>
<tr>
<th>Study</th>
<th>Number</th>
<th>Agent</th>
<th>WT:MT</th>
<th>ORR, MT:WT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lièvre et al37</td>
<td>76</td>
<td>Cetuximab plus chemotherapy</td>
<td>49:27</td>
<td>0 (0%):24 (49%)</td>
</tr>
<tr>
<td>De Roock et al38</td>
<td>113</td>
<td>Cetuximab</td>
<td>67:46</td>
<td>0 (0%):27 (41%)</td>
</tr>
<tr>
<td>Khambata-Ford et al41</td>
<td>80</td>
<td>Cetuximab</td>
<td>50:30</td>
<td></td>
</tr>
<tr>
<td>Amaro et al49</td>
<td>427</td>
<td>Panitumumab</td>
<td>243:184</td>
<td>0 (0%):31 (17%)</td>
</tr>
<tr>
<td>Tol et al40 (CAIRO-2)</td>
<td>582</td>
<td>CapeOx + bev</td>
<td>156:108</td>
<td>78 (50%):64 (59.2%)</td>
</tr>
<tr>
<td>Van Cutsem et al41</td>
<td>540</td>
<td>FOLFIRI</td>
<td>176:87</td>
<td>76 (43.2%):35 (40.2%)</td>
</tr>
<tr>
<td>(CRYSTAL)</td>
<td>315</td>
<td>FOLFIRI + cetuximab</td>
<td>172:105</td>
<td>102 (59.3%):38 (36.2%)</td>
</tr>
<tr>
<td>Bokemeyer et al42</td>
<td>82:77</td>
<td>FOLFOX-4</td>
<td>97:59</td>
<td>33 (34%):31 (52%)</td>
</tr>
<tr>
<td>Tveit et al43 (NORDIC FLOX)</td>
<td>566</td>
<td>FLOX</td>
<td>48:28</td>
<td>46 (47%):23 (30%)</td>
</tr>
<tr>
<td>Maugan et al44 (MRC COIN)</td>
<td>1,316</td>
<td>FOLFIRI/CapeOx</td>
<td>245:169</td>
<td>209 (57%):not available</td>
</tr>
</tbody>
</table>

**Abbreviations:** bev, bevacizumab; CapeOx, capecitabine plus oxaliplatin; EGFR, epidermal growth factor receptor; FLOX, 5-fluorouracil, folinic acid, oxaliplatin; FOLFIRI, folinic acid, 5-fluorouracil, and irinotecan; FOLFOX, oxaliplatin, folinic acid, and 5-fluorouracil; ORR, overall response rate; MT, mutant; WT, wild type.
13 mutation are analyzed separately. One analysis of patients treated with cetuximab suggests there is a statistical trend toward an OS and progression-free survival (PFS) benefit when cetuximab is added to chemotherapy (when compared with chemotherapy alone).45 A pooled analysis of three randomized studies of patients treated with panitumumab (either as monotherapy compared with best supportive care, or combined with FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan] or FOLFOX-4 [oxaliplatin, folinic acid, and 5-fluorouracil]) failed to demonstrate any panitumumab efficacy for patients with KRAS codon 13 tumors.46 At this time, the data are insufficient to recommend the use of anti-EGFR therapies in patients with KRAS codon 13 specific mutations. Most tissue analysis evaluating KRAS mutations by polymerase chain reaction (PCR) interrogate the tissue for codon 12 and 13 mutations; more recently, codon 61 and 146 KRAS mutations in CRC have been described. At this time, the prognostic significance, as well as the potential anti-EGFR predictive implications of KRAS codon 61 and 146 mutations are not known.47

Newer technologies, with higher sensitivity to detecting KRAS mutations, are being evaluated, which may improve the predictive efficacy of KRAS as a negative biomarker. Evaluation of tumor KRAS codon 12 and 13 mutation by direct sequencing, in addition to MALDI TOF (matrix-assisted laser desorption/ionization-time-of-flight) mass spectrometry, mutant-enriched PCR, and engineered mutant-enriched PCR, in 111 patients identified an additional 13 patients with KRAS mutations beyond the initial 43 patients identified by direct sequencing.48 Tumor KRAS mutations have also been detected in plasma cell-free DNA from CRC patients;49 these studies suggest that if validated as a biomarker, it may be possible in the future to perform tumor KRAS analysis on plasma. Studies of plasma mutant KRAS levels, evaluated by quantitative PCR, suggest evaluation of tumor mutations in plasma may be a viable source of tissue for KRAS and BRAF biomarker analysis evaluation.50

**Tumor BRAF mutation**

Similar to KRAS, BRAF is a proto-oncogene, which is located downstream of EGFR receptor; BRAF mutations are present in approximately 10% of CRC cases, most commonly the V600E point mutation.51,52 Therefore, the impact of this mutant signal molecule on cetuximab sensitivity has also been investigated in patients with wild-type KRAS CRC. A retrospective analysis of 79 KRAS wild-type patients showed that BRAF protocol-oncogene (BRAF V600E) was associated with resistance to cetuximab treatment in treatment refractory metastatic CRC patients.53 Another retrospective analysis also demonstrated the resistance to cetuximab treatment in tumors with BRAF V600E mutation and wild-type KRAS.54 Despite these preliminary studies supporting the fact that the presence of a BRAF mutation was a negative predictor of response to cetuximab, a large randomized Phase III clinical trial (the “COIN” trial), which evaluated the addition of the cetuximab to conventional chemotherapy (CapeOx [capecitabine plus oxaliplatin]) as a first-line treatment of advanced stage CRC patients, did not show any relationship between OS and PFS dependent on tumor BRAF mutation status.44 The difference observed in these clinical trials could be due to different treatment settings (palliative treatment compared with first-line treatment). Thus, the role of the BRAF mutation as a negative predictor of cetuximab efficacy is continuing to be studied.

**Tumor NRAS mutation**

Following the investigation of the biomarkers described above, the impact of other EGFR-related genes such NRAS was evaluated in clinical trials to understand its role in predicting survival. NRAS was found to be mutated in approximately 2.6%–4.0% of CRC cases.55 A retrospective analysis of 773 tumor samples from multiple centers showed that NRAS mutation was a negative predictor for the cetuximab response in patients treated with cetuximab plus chemotherapy.56 Another prospective study did not find any survival relationship between NRAS or KRAS mutations and cetuximab treatment.32 Because of the lack of convincing data in the literature, the precise biomarker implications of the presence of a tumor NRAS on cetuximab response is not known at this time.

**PIK3CA mutation**

PIK3CA is also a signal molecule of EGFR, and a mutant form has been suggested to be involved in carcinogenesis in many tumors.57 Since PIK3CA mutation may also change the signal transduction of EGFR, cetuximab efficacy was also investigated in metastatic CRC patients with PIK3CA mutation. Similar to KRAS, activating mutation of PIK3CA was found to be resistant to anti-EGFR treatment. A cohort of the 110 patients showed that none of the patients with PIK3CA mutation had objective response to either panitumumab or cetuximab.58 In another study, the authors reported that PIK3CA exon 9 mutation showed significantly less response to cetuximab and shorter PFS compared with wild-type PIK3CA in CRC patients.54 Although current available data suggest that both PIK3CA mutation and decreased expression of PTEN cause resistance to cetuximab therapy,
larger randomized prospective clinical trials are necessary to assess possible biomarker utility of these genes.

**Immunoglobulin G Fcγ receptor polymorphisms**

In vitro studies have demonstrated that cetuximab can induce antibody-dependent cellular cytotoxicity by activating immune system elements in various tumors regardless of KRAS mutation status. Initial clinical study results have pointed to a possible relationship between immunoglobulin G Fcγ receptor polymorphisms and cetuximab response, and recent large pooled data failed to demonstrated any survival association in metastatic CRC patients. In the latter study, the authors reported marginally better disease control in patients with KRAS-mutated tumors with favorable polymorphism, suggesting that the antibody-dependent cellular cytotoxicity occurring in the macrometastatic disease has very limited effect on the efficacy of cetuximab therapy.

**Tumor amphiregulin and epiregulin gene expression**

Since the anti-EGFR therapy targets the growth signaling in cancer cells, the impact of the external growth signal mediators has been investigated in CRC; when secreted in a paracrine fashion by tumor cells, it plays a role in promoting tumor progression. A study of 110 patients tested the role of epiregulin and amphiregulin in metastatic CRC patients who were treated with cetuximab monotherapy. Patients with metastatic CRC that have high expression of epiregulin and amphiregulin in their tumors showed better response to cetuximab therapy ($P=0.000015$ and $P=0.000025$, respectively), suggesting that local growth signals are also involved in the disease progression, and this paracrine and autocrine process can be reversed by blocking the EGFR via monoclonal antibodies to induce tumor regression. Another study also investigated these two ligands of EGFR in metastatic colorectal patients by measuring the gene expression in primary tumors by stratifying according to the KRAS mutation status. This study also demonstrated the correlation between higher growth hormone ligands and better PFS, but only in patients with wild-type KRAS mutation. There was no similar benefit in patients whose tumor was mutant-KRAS, indicating that KRAS-mutant CRC cells do not depend on local growth signals to survive and progress.

**Further considerations**

Recent studies have suggested that analysis of multiple mutations in the RAS/RAF kinase pathway may be more sensitive in determining those patients likely to be resistant to anti-EGFR therapy. In the Fire-3 (AIO KRKI-0306) Phase III trial, comparing FOLFIRI combined with either cetuximab or bevacizumab, patients underwent analysis of KRAS, NRAS, and BRAF mutations; in patients who received FOLFIRI plus cetuximab, the RAS wild-type subgroup (KRAS, BRAF, and NRAS), the objective response rate was 76% compared with 42.9%. These studies suggest that multiple biomarkers of the RAS pathway may be necessary to optimally identify patients unlikely to benefit from anti-EGFR therapy. Furthermore, additional studies have demonstrated that acquired resistance to anti-EGFR therapy may be secondary to clonal selection of tumors with mutations in the EGFR receptor ectodomain. KRAS amplification may also contribute to primary resistance to anti-EGFR monoclonal antibodies.

**Conclusion**

The current evidence from preclinical and clinical studies indicates that cetuximab as a monoclonal antibody has a potential reversing effect on EGFR-mediated growth signals in CRC cells and induces tumor suppression, and as a consequence, an increase in the survival of metastatic CRC patients. However, these benefits are observed in a limited number of patients with advance stage disease and certain pathological properties. Patients with KRAS mutations, specifically with KRAS codon 12 mutation, are unlikely to benefit from cetuximab treatment. While the data for KRAS p.G13D mutation is controversial, current guidelines do not recommend the use of this agent in patients whose tumor harbors this mutation. Accumulating evidence also suggests that mutations in other signal transduction molecules involved in EGFR signaling might also have an impact on cetuximab therapy outcomes, yet more evidence is required to establish the biomarker utility of these molecules. Available data also suggest that metastatic CRC patients with higher expression of local growth factor, such as amphiregulin and epiregulin and increased EGFR gene copy number, most probably benefit from monoclonal targeting in the absence of KRAS mutation.

Since molecularly targeting treatment by monoclonal antibodies results in a highly expensive economic burden, defining useful biomarkers to target the correct patient population is mandatory. The selection of patients who may potentially benefit from this agent not only decreases health costs but also avoids the side effects resulting from the use of cetuximab in patients who would not receive benefit from such therapy. Although molecular testing itself is associated with high health costs, the use of molecular biomarkers, by more carefully selecting patients for therapy, with higher certainty of efficacy, may lead to more cost-effective medical care.
Future studies may also look at different molecular subtypes of CRC, as identified by tumor gene expression profiling, and determine response to anti-EGFR monoclonal antibody therapy, as well as other pathway-specific inhibitors.65

Overall, cetuximab has been shown to be effective in metastatic CRC patients with irinotecan-resistance and has superior outcomes as a single agent compared with best supportive care. The addition of cetuximab to conventional chemotherapy in adjuvant settings in metastatic CRC patients could also potentially provide survival benefits. Combining with other targeting agents which inhibit signal transducing molecules involved in EGFR signaling will likely increase the efficacy of cetuximab treatment. However, the recently discovered diversity of active network signaling pathways in cancer cells appears to be a challenge for scientists in cancer research. Studies of biomarker exploration will have to take into account interactions beyond the tumor and incorporate knowledge of the tumor microenvironment and the immune response to therapy into biomarker discovery.

Disclosure
The authors report no conflicts of interest in this work.

References


